FoLix Hair Loss Treatment Expands Into Canada

FoLix™, the only US Food and Drug Administration-cleared fractional laser for hair loss, will now be made available in Canada, Lumenis Be. Ltd. announced.

Having debuted in the US in June 2024, FoLix was recently named the "Best Laser Treatment for Hair Loss" on NewBeauty's 2025 Beauty Awards list, highlighting the treatment's effectiveness powered by its groundbreaking approach.

FoLix's novel technology harnesses non-ablative fractional laser (NAFL) and proprietary technology tailored for scalp hair to stimulate hair follicles. It delivers precise pulses of laser that leverage the body's natural healing processes to stimulate hair follicles, enhance blood flow, and promote tissue regeneration. It can produce results in only four to six monthly sessions with no chemicals, needles, anesthesia, surgery or downtime.

"With FoLix, we're not just offering a treatment—we're empowering people to reclaim their confidence and feel like their best selves," Tzipi Ozer-Armon, CEO of Lumenis, said in a press release. "Today's expansion into Canada marks a pivotal milestone in our mission to transform the hair loss space with a solution that is science-backed, safe, and clinically proven. This momentum—reinforced by our NewBeauty award—fuels our commitment to accelerate access to FoLix worldwide."